Yes Bedger, selling now (below the entitlement price) was/is defo a bit premature.
Understand revenue capture has been poor and SP is not reflecting positivity. However, noting current momentum from partnerships and a company only listed around the on-set of COVID (with a recent push for commercialization) - I really see it oversold.
Next 4 quarters are crucial that being said. Management would really need to pull their socks up.
Add to My Watchlist
What is My Watchlist?
